JACOBIO-B News

JACOBIO-B: VOLUNTARY ANNOUNCEMENT CHINA CDE CLEARANCE FOR PHASE III CLINICAL TRIAL OF KRAS G12C INHIBITOR GLECIRASIB IN COMBINATION WITH CETUXIMAB IN PATIENTS WITH COLORECTAL CANCER

May 10 09:49 ET

JACOBIO-B: VOLUNTARY ANNOUNCEMENT SUBMISSION OF NEW DRUG APPLICATION FOR KRAS G12C INHIBITOR GLECIRASIB

May 6 09:40 ET

JACOBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 April 2024

May 6 04:32 ET

JACOBIO-B: FORM OF PROXY FOR THE 2024 ANNUAL GENERAL MEETING

Apr 26 05:08 ET

JACOBIO-B: NOTICE OF 2024 ANNUAL GENERAL MEETING

Apr 26 05:06 ET

JACOBIO-B: PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, PROPOSED RE-ELECTION OF DIRECTORS, PROPOSED CHANGE OF AUDITOR AND NOTICE OF ANNUAL GENERAL MEETING

Apr 26 05:05 ET

JACOBIO-B: PROPOSED CHANGE OF AUDITOR

Apr 24 10:27 ET

JACOBIO-B: 2023 ANNUAL REPORT

Apr 24 08:48 ET

JACOBIO-B: VOLUNTARY ANNOUNCEMENT JACOBIO PRESENT ED CLINICAL DATA OF PARP7 INHIBITOR JAB-26766 AND P53 REACTIVATOR JAB-30355 AT THE AACR 2024

Apr 9 07:26 ET

JACOBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March 2024

Apr 3 04:58 ET

JACOBIO-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023

Mar 28 10:26 ET

JACOBIO-B: DATE OF BOARD MEETING

Mar 18 04:38 ET

JACOBIO-B: VOLUNTARY ANNOUNCEMENT

Mar 5 05:27 ET

JACOBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 29 February 2024

Mar 4 03:40 ET

JACOBIO-B: Notification Letter and Reply Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications

Mar 1 03:05 ET

JACOBIO-B: Notification Letter and Reply Form to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications

Mar 1 02:59 ET

JACOBIO-B: VOLUNTARY ANNOUNCEMENT JACOBIO RECEIVED US FDA INVESTIGATIONAL NEW DRUG CLEARANCE FOR P53 Y220C Activator JAB-30300

Feb 29 23:09 ET

JACOBIO-B: VOLUNTARY ANNOUNCEMENT THE REGISTRATIONAL PHASE III CLINICAL TRIAL OF SHP2 INHIBITOR JAB-3312 IN COMBINATION WITH KRAS G12C INHIBITOR GLECIRASIB APPROVED BY THE CENTER FOR DRUG EVALUATION (CDE) OF THE NMPA

Feb 18 06:50 ET

JACOBIO-B: Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 January 2024

Feb 5 03:42 ET

JACOBIO-B: VOLUNTARY ANNOUNCEMENT JACOBIO PRESENTED CLINICAL DATA OF KRAS G12C INHIBITOR GLECIRASIB IN PATIENTS WITH PANCREATIC CANCER AND OTHER SOLID TUMORS AT THE 2024 ASCO GI

Jan 21 05:08 ET